Apimeds Pharmaceuticals US Inc
APUS1.650USD
-0.090-5.17%
交易中 （美东）报价延迟15分钟
13.04M总市值
亏损市盈率 TTM
关于 Apimeds Pharmaceuticals US Inc 公司
Apimeds Pharmaceuticals US, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in developing Apitox, an intradermally administered bee venom-based toxin. It is focused on developing Apitox as a potential osteoarthritis (OA) treatment for patients with knee pain who failed to respond adequately to conservative non- pharmacologic therapy and simple analgesics.
公司简介
公司代码APUS
公司名称Apimeds Pharmaceuticals US Inc
上市日期May 09, 2025
CEOMr. Erik C. Emerson
员工数量2
证券类型Ordinary Share
年结日May 09
公司地址100 Matawan Road
城市MATAWAN
上市交易所NYSE American Consolidated
国家United States of America
邮编07747
电话18482015010
网址https://www.apimedsus.com/
公司代码APUS
上市日期May 09, 2025
CEOMr. Erik C. Emerson
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Erik C. Emerson
Mr. Erik C. Emerson
Chief Executive Officer, Director
Chief Executive Officer, Director
750.00K
--
Mr. Jakap Koo
Mr. Jakap Koo
Director
Director
643.88K
+4.63%
Dr. Christopher Kim, M.D.
Dr. Christopher Kim, M.D.
Chairman of the Board, Chief Medical Officer
Chairman of the Board, Chief Medical Officer
277.50K
--
Ms. Elona Kogan, Esq.
Ms. Elona Kogan, Esq.
Independent Director
Independent Director
--
--
Ms. Carol O'Donnell
Ms. Carol O'Donnell
Independent Director
Independent Director
--
--
Dr. Bennett Weintraub, Ph.D.
Dr. Bennett Weintraub, Ph.D.
Independent Director
Independent Director
--
--
Dr. Hankil Yoon, Ph.D.
Dr. Hankil Yoon, Ph.D.
Independent Director
Independent Director
--
--
Mr. Erick Frim
Mr. Erick Frim
Chief Financial Officer
Chief Financial Officer
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Erik C. Emerson
Mr. Erik C. Emerson
Chief Executive Officer, Director
Chief Executive Officer, Director
750.00K
--
Mr. Jakap Koo
Mr. Jakap Koo
Director
Director
643.88K
+4.63%
Dr. Christopher Kim, M.D.
Dr. Christopher Kim, M.D.
Chairman of the Board, Chief Medical Officer
Chairman of the Board, Chief Medical Officer
277.50K
--
Ms. Elona Kogan, Esq.
Ms. Elona Kogan, Esq.
Independent Director
Independent Director
--
--
Ms. Carol O'Donnell
Ms. Carol O'Donnell
Independent Director
Independent Director
--
--
Dr. Bennett Weintraub, Ph.D.
Dr. Bennett Weintraub, Ph.D.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月2日 周三
更新时间: 7月2日 周三
持股股东
股东类型
持股股东
持股股东
占比
Apimeds, Inc.
37.90%
Inscobee, Inc.
17.52%
Dominus IB, Inc
6.91%
Emerson (Erik C)
6.48%
Koo (Jakap)
5.56%
Other
25.62%
持股股东
持股股东
占比
Apimeds, Inc.
37.90%
Inscobee, Inc.
17.52%
Dominus IB, Inc
6.91%
Emerson (Erik C)
6.48%
Koo (Jakap)
5.56%
Other
25.62%
股东类型
持股股东
占比
Corporation
67.52%
Individual Investor
14.44%
Other
18.04%
机构持股
更新时间: 7月2日 周三
更新时间: 7月2日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
7
9.49M
81.96%
+7.39M
2025Q2
7
9.49M
81.96%
+7.39M
2025Q1
2
2.10M
18.15%
+2.10M
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Apimeds, Inc.
4.39M
37.9%
+4.39M
--
May 12, 2025
Inscobee, Inc.
2.03M
17.52%
+544.04K
+36.65%
May 12, 2025
Dominus IB, Inc
800.00K
6.91%
+800.00K
--
May 09, 2025
Emerson (Erik C)
750.00K
6.48%
+750.00K
--
May 16, 2025
Koo (Jakap)
643.88K
5.56%
+28.50K
+4.63%
May 12, 2025
Seed 1 ho
600.00K
5.18%
+600.00K
--
May 09, 2025
Kim (Christopher)
277.50K
2.4%
+277.50K
--
May 16, 2025
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
